China Largest Manufacturer factory sales Cyclovirobuxine D CAS 860-79-7 CAS NO.860-79-7

                                PRODUCT DETAILS       

Cyclovirobuxin D Basic information Product Name: Cyclovirobuxin D Synonyms: CYCLOVIROBUXINE;CYCLOVIROBUXINE D;9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N',4,4,14-PENTAMETHYL-, (3,5,20S)-;Cyclovirobuxin D(Bebuxine,Cyclovirobuxine D, NSC 91722 );Cyclovirobuxin D(Bebuxine);9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3β,5α,16α,20S)-;Cyclovirobuxine D, >=98%;NSC91722 CAS: 860-79-7 MF: C26H46N2O MW: 402.66 EINECS:   Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Inhibitors;Alkaloids Mol File: 860-79-7.mol   Cyclovirobuxin D Chemical Properties Melting point  220-221 °C (decomp)(Solv: acetone (67-64-1)) Boiling point  524.75°C (rough estimate) density  0.9815 (rough estimate) refractive index  1.5300 (estimate) pka 15.12±0.70(Predicted) CAS DataBase Reference 860-79-7(CAS DataBase Reference)   Safety Information Safety Statements  24/25 HS Code  29420000 Toxicity LD50 oral in mouse: 293mg/kg MSDS Information   Cyclovirobuxin D Usage And Synthesis Description A Buxus alkaloid of the steroidal class, this base has been found in the strong base fraction of the alkaloidal extract from Buxus microphylla Sieb. et Zucco var. suffruticosa and B. microphylla Sieb. et Zucco var. suffruticosa Makino forma major. It is dextrorotatory having a specific rotation of [α]23D + 98° (c 4.40,CHC13)and yields a series of salts and derivatives including the dihydrobromide, m.p. 288-292°C (dec.); dihydriodide, m.p. 276-8°C (dec.); diperchlorate, m.p. 244- 5°C (dec.); dioxalate as an amorphous powder, m.p. 264-7°C (dec.): the N:Ndiacetyl derivative, m.p. 278-281°C (dec.) with [α]24D + 10° (c 1.94, CHC13) and the O,N,N-triacetyl derivative, m.p. 246-8°C with [α]24D - 12° (c 2.40, CHCI3)· The structure and stereochemistry of the base have been elucidated from chemical analysis, spectroscopic evidence and comparison with other alkaloids of this class. Physical properties Appearance: colorless needle crystals. Solubility: sparingly soluble in acetone; slightly soluble in water; freely soluble in chloroform; soluble in methanol and ethanol. Melting point: 219–222 °C. History Cyclovirobuxine in the treatment of coronary heart disease began in 1969 . The medical teams of Chinese People’s Liberation Army No.86489 explored a treatment of coronary heart disease named Guo, prescription composed of Buxus microphylla (huangyangmu), Salvia miltiorrhiza Bge. (danshen), Ligustici Chuanxiong Rhizoma (chuanxiong), Belamcandae Rhizoma (shegan), Radix Aristolochiae (qingmuxiang) and Asari Radix et Rhizoma (xixin). In 1978, the Anhui Huangyang Research Cooperation Group carried out systematic experiments to determine the chemical structure and the separation and identification method of cyclovirobuxine by melting point determination, thin-layer chromatography, infrared spectroscopy, mass spectrometry and NMR . Three studies containing more than 300 cases of coronary heart disease patients treated with cyclovirobuxine showed that this drug can significantly improve angina, chest tightness, arrhythmia and other symptoms caused by coronary heart disease. Uses Cyclovirobuxine D is a potential preventative agent of cardiac dysfunction. Indications It is mainly used for the treatment of cardiovascular and cerebrovascular diseases in China, such as the coronary heart disease, arrhythmia, cerebral arteriosclerosis, cerebral embolism and brain vascular accident which are caused by insufficiency of cerebral blood supply. Pharmacology Pharmacological studies have shown that cyclovirobuxine has a positive inotropic effect on the heart that may predominantly be due to the inhibition of cardiomyocyte membrane Na+-K+-ATPase activity and promotion of myocardial extracellular Ca2+ influx and cardiomyocyte Ca2+ release. Moreover, cyclovirobuxine could markedly reduce myocardial oxygen consumption and increase coronary blood flow, suggesting that it has definite anti-myocardial ischemia effect. Experiments also showed that cyclovirobuxine could induce marked inhibition of myocardial ischemia infarction and enhancement of anoxia tolerance in mice . Besides, cyclovirobuxine could have protective effect on the acute experimental cerebral ischemia in mice by bilateral ligation of common carotid arteries, prolong the life span of mice, increase blood flow and decrease the formation of thrombus during cerebral ischemia . In vitro experiments have also shown that cyclovirobuxine has neuroprotective effects on neurons and restrains PC12 cells from excitatory amino acid-induced injury . Clinical Use After decades of clinical observation, cyclovirobuxine has the therapeutic role of anti-myocardial ischemia and antiarrhythmia and protects against acute cerebral ischemia. In addition, cyclovirobuxine can cross the blood-brain barrier and improve brain microcirculation and oxygen supply to treat cerebral arteriosclerosis insufficiency. References Nakano, Terao, Tetrahedron Lett., 1035, 1045, (1964) Brown, Kupchan, J. Amer. Chem. Soc., 86, 4414, 4424 (1964) Nakano, Terao,J. Chem. Soc., 4512, 4537 (1965) Nakano, Hasegawa, ibid, 6688 (1965)   Cyclovirobuxin D Preparation Products And Raw materials

                                                                About Our Group

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

                                                                      Our Group profiles

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse 

                                                       Product information

Cyclovirobuxin D Basic information Product Name: Cyclovirobuxin D Synonyms: CYCLOVIROBUXINE;CYCLOVIROBUXINE D;9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N',4,4,14-PENTAMETHYL-, (3,5,20S)-;Cyclovirobuxin D(Bebuxine,Cyclovirobuxine D, NSC 91722 );Cyclovirobuxin D(Bebuxine);9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3β,5α,16α,20S)-;Cyclovirobuxine D, >=98%;NSC91722 CAS: 860-79-7 MF: C26H46N2O MW: 402.66 EINECS:   Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Inhibitors;Alkaloids Mol File: 860-79-7.mol   Cyclovirobuxin D Chemical Properties Melting point  220-221 °C (decomp)(Solv: acetone (67-64-1)) Boiling point  524.75°C (rough estimate) density  0.9815 (rough estimate) refractive index  1.5300 (estimate) pka 15.12±0.70(Predicted) CAS DataBase Reference 860-79-7(CAS DataBase Reference)   Safety Information Safety Statements  24/25 HS Code  29420000 Toxicity LD50 oral in mouse: 293mg/kg MSDS Information   Cyclovirobuxin D Usage And Synthesis Description A Buxus alkaloid of the steroidal class, this base has been found in the strong base fraction of the alkaloidal extract from Buxus microphylla Sieb. et Zucco var. suffruticosa and B. microphylla Sieb. et Zucco var. suffruticosa Makino forma major. It is dextrorotatory having a specific rotation of [α]23D + 98° (c 4.40,CHC13)and yields a series of salts and derivatives including the dihydrobromide, m.p. 288-292°C (dec.); dihydriodide, m.p. 276-8°C (dec.); diperchlorate, m.p. 244- 5°C (dec.); dioxalate as an amorphous powder, m.p. 264-7°C (dec.): the N:Ndiacetyl derivative, m.p. 278-281°C (dec.) with [α]24D + 10° (c 1.94, CHC13) and the O,N,N-triacetyl derivative, m.p. 246-8°C with [α]24D - 12° (c 2.40, CHCI3)· The structure and stereochemistry of the base have been elucidated from chemical analysis, spectroscopic evidence and comparison with other alkaloids of this class. Physical properties Appearance: colorless needle crystals. Solubility: sparingly soluble in acetone; slightly soluble in water; freely soluble in chloroform; soluble in methanol and ethanol. Melting point: 219–222 °C. History Cyclovirobuxine in the treatment of coronary heart disease began in 1969 . The medical teams of Chinese People’s Liberation Army No.86489 explored a treatment of coronary heart disease named Guo, prescription composed of Buxus microphylla (huangyangmu), Salvia miltiorrhiza Bge. (danshen), Ligustici Chuanxiong Rhizoma (chuanxiong), Belamcandae Rhizoma (shegan), Radix Aristolochiae (qingmuxiang) and Asari Radix et Rhizoma (xixin). In 1978, the Anhui Huangyang Research Cooperation Group carried out systematic experiments to determine the chemical structure and the separation and identification method of cyclovirobuxine by melting point determination, thin-layer chromatography, infrared spectroscopy, mass spectrometry and NMR . Three studies containing more than 300 cases of coronary heart disease patients treated with cyclovirobuxine showed that this drug can significantly improve angina, chest tightness, arrhythmia and other symptoms caused by coronary heart disease. Uses Cyclovirobuxine D is a potential preventative agent of cardiac dysfunction. Indications It is mainly used for the treatment of cardiovascular and cerebrovascular diseases in China, such as the coronary heart disease, arrhythmia, cerebral arteriosclerosis, cerebral embolism and brain vascular accident which are caused by insufficiency of cerebral blood supply. Pharmacology Pharmacological studies have shown that cyclovirobuxine has a positive inotropic effect on the heart that may predominantly be due to the inhibition of cardiomyocyte membrane Na+-K+-ATPase activity and promotion of myocardial extracellular Ca2+ influx and cardiomyocyte Ca2+ release. Moreover, cyclovirobuxine could markedly reduce myocardial oxygen consumption and increase coronary blood flow, suggesting that it has definite anti-myocardial ischemia effect. Experiments also showed that cyclovirobuxine could induce marked inhibition of myocardial ischemia infarction and enhancement of anoxia tolerance in mice . Besides, cyclovirobuxine could have protective effect on the acute experimental cerebral ischemia in mice by bilateral ligation of common carotid arteries, prolong the life span of mice, increase blood flow and decrease the formation of thrombus during cerebral ischemia . In vitro experiments have also shown that cyclovirobuxine has neuroprotective effects on neurons and restrains PC12 cells from excitatory amino acid-induced injury . Clinical Use After decades of clinical observation, cyclovirobuxine has the therapeutic role of anti-myocardial ischemia and antiarrhythmia and protects against acute cerebral ischemia. In addition, cyclovirobuxine can cross the blood-brain barrier and improve brain microcirculation and oxygen supply to treat cerebral arteriosclerosis insufficiency. References Nakano, Terao, Tetrahedron Lett., 1035, 1045, (1964) Brown, Kupchan, J. Amer. Chem. Soc., 86, 4414, 4424 (1964) Nakano, Terao,J. Chem. Soc., 4512, 4537 (1965) Nakano, Hasegawa, ibid, 6688 (1965)   Cyclovirobuxin D Preparation Products And Raw materials